SAFETY Meeting Minutes
UAMS IBC

MEETING TIME RECORDS

Meeting start time: 10/2/2026 12:01 PM
Meeting end time: 10/2/2026 12:17 PM
Meeting type: Virtual

Name of Regular/Alternate Member	Status (Member or Alternate)	Present by Teleconference?
Ha-Neui Kim	Member	Yes
Matthew Jorgenson	Member	Yes
Robert Hunter	Member	No
Lindsey Clark	Member	Yes
James Bishop	Member	No
Youssef Aachoui	Member	Yes
Jia Liu	Member	Yes
Yuet-Kin Leung	Member	Yes
Melaney Gee	Member	Yes
Mark Manzano	Member	Yes
Antino Allen	Member	No
KyoungHyun Kim	Member	No
James Townsend	Member	Yes
Shengyu Mu	Member	Yes
Kikumi Ono-Moore	Ex Officio	Yes
Zhiqiang Qin	Member	Yes
Andre Ewell	Member	Yes

QUORUM INFORMATION

Number of SAFETY members on the roster: 16
Number required for quorum: 8
Quorum: Yes

All members present via teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

ATTENDANCE STATUS AND VOTING KEY	
ABSTAIN:	Present for the vote but not voting "For" or "Against."
ABSENT:	Absent for discussion and voting for reasons other than a conflict of interest.
RECUSED:	Absent from the meeting during discussion and voting because of a conflict of interest.
SUBSTITUTION:	When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member serves as a substitute for the regular member this identifies the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions.

GUEST NAMES
Dr. David Neale
Cole Burmingham

Previous Meeting minutes approved: Yes

REVIEW OF SUBMISSIONS

The review and discussion of the protocols listed below included the following elements: the agents involved and their characteristics; types of manipulations planned; the source(s) and nature of the nucleic acid sequences; the host organism(s) and vector(s) to be utilized; whether expression of a foreign gene is intended and, if so, the specific protein(s) to be produced; the containment conditions to be applied, including biosafety level and any special provisions; and the relevant sections of the NIH Guidelines.

All IBC members present were reminded to identify any conflicts of interest as each registration was reviewed.

For each protocol reviewed, it was confirmed that the Principal Investigator (PI) and laboratory personnel have received appropriate training in the safe conduct of research.

Initial Protocol

1. Review of SPROTO202600000060

Title:	Wnt/Ca2+ in TNBC
Investigator:	Hongjiang Si
Submission ID:	SPROTO202600000060
Description:	In this project, we aim to establish a robust breast cancer model capable of indicating intracellular Ca2+ levels and discover novel targets in Wnt/Ca2+ signaling pathway to overcome triple-negative breast cancer (TNBC) metastasis and drug resistance. We will employ a highly sensitive, genetically encoded Ca2+ indicator to directly measure Wnt-induced Ca2+ mobilization in 2D breast cancer cell lines and 3D tumor organoids. With genetic knockdown of key signaling components and pharmaceutical inhibition, we aim to discover the critical players regulating this signaling pathway in breast cancer adhesion, metastasis, and chemo-resistance. This comprehensive research proposal will not only shed light on the intricate mechanisms governing Wnt/Ca2+ signaling in TNBC metastasis but also provide novel insights into targeting TNBC progression and overcoming drug resistance from a fresh perspective.
Agent Containment:	Biological Containment Levels: • E. coli: BSL-2 • HCC1806 Cell Line: BSL-2 • Lentivirus: BSL-2 • Human Vascular Endothelial Cells: BSL-2 • 293T: BSL-2 • MCF10A Human Cell Line: BSL-2 • SUM-159: BSL-2 • SUM-149: BSL-2 • HCC-1143: BSL-2 • MDA-MB-231 (Human TNBC cell line): BSL-2
Applicable NIH Guidelines:	• Section III-D • Section III-D-3-a

a. **Determination:** Modifications Required

b. **Required modifications:**
Please review and respond to comments throughout the protocol; make any necessary changes in the protocol. Contact BSO Lindsey Clark (LClark4@uams.edu) with any questions. Thank you!

c. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	4
Abstained:	0

REVIEW OF OTHER AGENDA ITEMS

1. The committee was updated on recent staff changes in the Biosafety Office.
2. Updates to committee membership were shared with the committee.
3. The committee was made aware of the draft NIH Biosafety Policy and encouraged to review and submit comments by October 19. 2026.
4. Administrative approvals were acknowledged by the committee.